SCHEMBL794260

SCHEMBL794260

O=S(=O)(Nc1cccc(-c2nnn[nH]2)c1)c1ccc(Cl)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 5/20 0.53
ITGA1 P56199 4/20 0.51
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
ALOX12 P18054 1/20 0.46
NLRP1 Q9C000 1/20 0.46
PPARG P37231 3/20 0.43
CYP3A4 P08684 1/20 0.43
SLC40A1 Q9NP59 1/20 0.43
RAB9A P51151 1/20 0.43
LNPEP Q9UIQ6 1/20 0.43
SGK1 O00141 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL793284 0.91 ALDH1A1 (0.52) PFKFB3MEN1KMT2AMAPTRAB9A
SCHEMBL793856 0.89 PFKFB3 (0.67) PFKFB3LMNAMAPTLNPEPSGK1
SCHEMBL794311 0.88 PFKFB3 (0.65) PFKFB3MEN1KMT2ALMNAMAPT
SCHEMBL793555 0.86 PFKFB3 (0.66) PFKFB3MEN1KMT2ALMNAMAPT
SCHEMBL794222 0.86 PFKFB3 (0.56) PFKFB3CYP3A4SLC40A1LNPEPGAA
SCHEMBL793853 0.86 PFKFB3 (0.49) PFKFB3KMT2ALMNAMAPTRAB9A
SCHEMBL793409 0.85 PFKFB3 (0.55) PFKFB3MEN1KMT2ALMNACYP3A4
SCHEMBL792880 0.84 PFKFB3 (0.54) PFKFB3MEN1KMT2ALMNAMAPT
SCHEMBL793550 0.83 MAPT (0.56) PFKFB3MEN1KMT2ALMNAMAPT
SCHEMBL793762 0.83 PFKFB3 (0.47) PFKFB3KMT2ALMNAMAPTSLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US claimed
EP-2616450-A2 SULFONAMIDE COMPOUNDS Kancera AB (SE) 2013-07-24 EP claimed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US claimed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 PFKFB3 1/4885ITGA1 3432/4885MEN1 3253/4885
US-20130172339-A1 SULFONAMIDE COMPOUNDS SULT1A1, STS, ARSA PFKFB3 952/4885ITGA1 2666/4885MEN1 3971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.